Phase 3 Open-Label, Study of OPC-41061 [tolvaptan] in Subjects With Cardiac-Induced Edema (Congestive Heart Failure) — an Investigation of the Safety of Treatment Beyond 7 Days and the Effect of Dose Escalation to 30 mg

Trial Profile

Phase 3 Open-Label, Study of OPC-41061 [tolvaptan] in Subjects With Cardiac-Induced Edema (Congestive Heart Failure) — an Investigation of the Safety of Treatment Beyond 7 Days and the Effect of Dose Escalation to 30 mg

Completed
Phase of Trial: Phase III

Latest Information Update: 19 May 2016

At a glance

  • Drugs Tolvaptan (Primary)
  • Indications Heart failure
  • Focus Pharmacodynamics; Registrational
  • Sponsors Otsuka Pharmaceutical
  • Most Recent Events

    • 24 Dec 2013 Last checked against ClinicalTrials.gov record.
    • 16 Dec 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 14 Jul 2008 Status changed from recruiting to in progress as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top